BGLC — Bionexus Gene Lab Income Statement
0.000.00%
Last trade - 00:00- $5.32m
- $4.03m
- $7.42m
Annual income statement for Bionexus Gene Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 13.4 | 10.9 | 9.77 | 9.51 | 7.42 |
| Cost of Revenue | |||||
| Gross Profit | 2.27 | 1.26 | 1.33 | 1.29 | 1.09 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 12.3 | 11.2 | 12.4 | 11.1 | 10.4 |
| Operating Profit | 1.04 | -0.304 | -2.61 | -1.57 | -2.97 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 1.04 | -0.304 | -2.61 | -1.59 | -2.98 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.752 | -0.356 | -2.63 | -1.6 | -2.98 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.752 | -0.356 | -2.63 | -1.6 | -2.98 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.752 | -0.356 | -2.63 | -1.6 | -2.98 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.527 | -0.247 | -1.66 | -0.883 | -1.61 |